[HTML][HTML] Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
H Je, GH Nam, GB Kim, W Kim, SR Kim… - Journal of Controlled …, 2021 - scholar.korea.ac.kr
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
H Je, GH Nam, GB Kim, W Kim… - … : official journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
H Je, GH Nam, GB Kim, W Kim, SR Kim… - Journal of Controlled …, 2021 - pure.korea.ac.kr
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
H Je, GH Nam, GB Kim, W Kim, SR Kim… - Journal of Controlled …, 2021 - research.knu.ac.kr
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages.
H Je, GH Nam, GB Kim, W Kim, SR Kim… - Journal of Controlled …, 2021 - europepmc.org
Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …
therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the …